Cell and Gene Therapy Manufacturing Forum

With the likes of Kymriah and Yescarta making headlines over the last 12 months for their US and EU approvals, the cell and gene therapy market continues to grow in size, value and potential.

From curing cancer to addressing ultra rare diseases, our industry’s innovators and experts have turned to ATMP-based therapies as a means of transforming the treatment landscape, and offering life saving treatments to those in critical need.

With a growing number of novel therapies continuing to progress towards commercialisation, and increased pressures on process scalability and regulatory compliance, manufacturing ATMP-based products requires a highly specialised and technical approach.

Given the unique challenges in the CGT manufacturing environment, we know that the industry needs an equally unique and focused forum so you can benchmark your processes against the market, implement process innovation and drive your product from manufacture to market.

That’s why the 2019 Cell and Gene Therapy Manufacturing Forum is our biggest yet. With content from over 18 industry leaders, this year will deliver more industry insights, more expert guidance and more networking so you can leave with practical steps to ensure your manufacturing capabilities are efficient, compliant and commercial.